Abstract
Objective To evaluate the clinical performance and safety of the ONIRY system for obstetric anal sphincter injuries (OASI) detection versus three-dimensional endoanal ultrasound (EAUS).
Design A prospective, comparative, multicentre, international study. Setting: Poland, Czechia, Slovakia, and Spain.
Population 152 women between the first moments up to 8 weeks after vaginal delivery.
Methods Participants underwent EAUS and were allocated to groups based on OASIS classification: A (no perineal tear), B (1st or 2nd degree tear), or C (3rd or 4th degree, anal sphincters affected). Electric impedance was measured in the anal canal using the ONIRY system. The primary endpoint was the diagnostic outcome of impedance spectroscopy versus EAUS. Adverse events were collected. Part II involved in silico modelling and 10-time 10-fold cross-validation for automated analysis.
Main Outcome Measures Accuracy, sensitivity, and specificity.
Results 30 women were allocated to group A, 61 to group B, and 61 to group C. The diagnostic outcome was determined for 147 participants. The accuracy, sensitivity, and specificity of the ML-assisted impedance spectroscopy were 87.0 ± 0.5%, 90.6 ± 2.0%, and 84.6 ± 1.9%, respectively, compared with EAUS. After data cleaning, the performance metrics of the proposed final ML model for ONIRY were: 90.0 ± 0.4%, 90.0 ± 1.2%, and 90.0 ± 0.7%, respectively. No adverse device effects or deficiencies were observed.
Conclusion ML-assisted impedance spectroscopy offers a safe and accurate method for rapid OASI detection. This approach could effectively complement digital rectal examination in obstetric settings, supporting timely postpartum care.
Funding information The study was financed by the Polish National Centre for Research and Development (POIR.01.01.01-00-0726/18).
Key Message With 90% accuracy, the ONIRY system’s ML-assisted impedance spectroscopy offers a reliable, non-invasive method for detecting obstetric anal sphincter injuries, supporting timely postpartum diagnosis.
Competing Interest Statement
K.B. is a founder and management board member at OASIS Diagnostics, an author of the related patent and R&D strategy, independent consultant, and trainer of Takeda. M.M., M.R., K.K., and P.I. are staff of OASIS Diagnostics. A.S. is an independent consultant of Ethicon, Takeda, Pfizer, Sofar. M.UM. is an independent consultant of Regen Lab. H.H., P.J., M.UM., E.D., and E.GD. received remuneration as a study investigator. H.H., C.R., and A.S. are independent consultants and members of the OASIS Diagnostics' Scientific Advisory Board. Others declare no conflicts of interest.
Clinical Trial
NCT04903977
Funding Statement
The study was funded by the European Union as part of the Fast Track program, conducted in Poland by the National Centre for Research and Development (POIR.01.00.01-00-0726/18).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the ethics committees respective for each study site: on 19 March 2021 by Ethics Committee of the Institute for Maternal and Child Care (no. 1/19.03.2021), on 27 April 2021 by Ethics Committee for Research with Medicines of the Health Areas of Leon and Bierzo (no. 2186), on 9 June 2021 by Ethics Committee of the University Hospital of Brno (no. 47/21Zdrav.), on 14 October 2021 by Ethics Committee at the Regional Medical Chamber in Warsaw (no. KB/1362/21) and on 25 July 2022 by Ethics Committee at AGEL Hospital Kosice-Saca (no. ONIRY 3/2/2020).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to increase the readability and clarify the study design and aim.
Data Availability
Data sharing is not applicable to this article due to legal and privacy issues.
